At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
In Brief
A Phase 2 clinical trial evaluating Vemurafenib, Cobimetinib, and 2 other interventions for BRAF V600E Mutation Present and Papillary Craniopharyngioma. Active but no longer recruiting, targeting 24 participants across 106 sites.
Signals
Detailed Summary
This phase II trial studies how well vemurafenib and cobimetinib work in treating patients with BRAF V600E mutation positive craniopharyngioma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Timeline
Arms & Interventions
Patients receive vemurafenib PO BID on day 1-28 and cobimetinib PO QD on days 1-21. Treatment repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. Patients may then receive radiation therapy, surgery, or continued treatment with vemurafenib and cobimetinib at the discretion of the treating physician.
Interventions
Given PO
Given PO
Correlative studies
Ancillary studies